“Alternate antibody formats have the potential to be game changers – not only do they expand the repertoire of diseases that can be treated by antibody-based products, but also offer the promise of lower-cost products in comparison to traditional antibodies.  As more clinical data is obtained on these engineered and alternate antibody formats, these technologies could pave the way for broader access pathways to life-altering mAb therapies.”  —IAVI and Wellcome (2020)   

abOde therapeutics was founded by seasoned leaders and world-class scientists. The vision is to unlock the vast potential of a class of next-generation antibodies termed single-domain antibodies (VHH or nanobodies) to create blockbuster therapeutics that can serve patients with intractable diseases in the U.S. and around the world.     

Interest in and recognition of the biomedical potential of nanobodies is increasing rapidly.  For example, the first EMA- and USFDA-approved 28-kDa nanobody is the bivalent caplacizumab for treatment of thrombotic thrombocytopenic purpura.  In another high-profile industry development, Sanofi announced in June 2018 that it had completed its $4.8 billion acquisition of Ablynx, a biopharmaceutical company based in Belgium that developed proprietary therapeutic proteins based on nanobodies.       

According to recent market research reported by The Insight Partners, the global monoclonal antibodies market, valued at $111 billion in 2021, is projected to reach $243 billion by 2028.     

abOde intends to pursue proprietary programs in autoimmune diseases, radiopharmaceuticals, cancer, and other areas where its technology offers compelling potential advantages.  Each program will be guided by appropriate members of the scientific advisory network, industry experts, and leading academicians.     

Major elements of abOde’s business strategy include developing a portfolio of product candidates (especially those with an accelerated path to market), licensing multiple technology platforms, forming relationships with corporate partners, and operating with minimal overhead until recurring revenues are established.  These aspects of abOde's business strategy reduce regulatory and commercial risk, reduce the company’s reliance on the capital markets, and increase the likelihood of a near-term product success.     

abOde and its products will be well positioned to have significant societal impact. .